Puma Biotechnology (PBYI) Operating Margin (2017 - 2026)

Puma Biotechnology has reported Operating Margin for 10 years, with the latest figure at 8.54% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin fell 1720.0% year-over-year to 8.54%; the trailing twelve-month figure through Mar 2026 stood at 12.98% (down 303.0% YoY), and the FY2025 full-year result was 16.33%, up 290.0% from the prior year.
• Operating Margin for Q1 2026 stood at 8.54%, down from 22.67% in the prior quarter.
• The five-year high for Operating Margin was 27.41% in Q3 2024, with the low at 8.54% in Q1 2026.
• Historically, Operating Margin has averaged 10.61% across 5 years, with a median of 11.43% in 2022.
• The largest YoY upside for Operating Margin was 5142 bps in 2022 against a maximum downside of 2216 bps in 2022.
• Puma Biotechnology's Operating Margin stood at 11.43% in 2022, then surged by 79 bps to 20.5% in 2023, then grew by 10 bps to 22.62% in 2024, then gained by 0 bps to 22.67% in 2025, then slumped by 138 bps to 8.54% in 2026.
• The last three Operating Margin figures came in at 8.54% (Q1 2026), 22.67% (Q4 2025), and 17.57% (Q3 2025), per Business Quant data.